CLINICAL TRIAL / NCT05468697

Inclusion Criteria: - Has a histologically confirmed diagnosis of unresectable Stage IV (per American Joint Committee on Cancer [AJCC], 8th Edition) RCC with clear-cell component - Has had disease progression on or after having received at least 2 systemic treatments for unresectable Stage IV RCC with prior anti-programmed cell death 1 ligand 1 (PD-1/L1) and a vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) in sequence or in combination - Has measurable disease per RECIST 1.1 as assessed by the investigator and verified by blinded independent central review (BICR) - Has recovered from all AEs due to previous therapies Exclusion Criteria: - Has hypoxia, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen - Has a known additional malignancy that is progressing or has required active treatment within the past 3 years - Has known central nervous system (CNS) metastases and/or carcinomatous meningitis - Has clinically significant cardiac disease - Has moderate to severe hepatic impairment - Has a known history of human immunodeficiency virus (HIV) infection - Has a history of hepatitis B (HBV) or known active hepatitis C (HCV) infection - Has received prior treatment of belzutifan or palbociclib - Has received prior radiotherapy ≤2 weeks prior to first dose of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids - Has had major surgery ≤3 weeks prior to first dose of study intervention - Has received colony-stimulating factors (eg, granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin [EPO]) ≤28 days prior to the first dose of study intervention